Posted by Michael Wonder on 07 Dec 2022
Migraine Foundation submits application to PHARMAC to fund Emgality
5 December 2022 - Migraine Foundation Aotearoa New Zealand has submitted a consumer application to Pharmac to fund Emgality (galcanezumab) for the treatment of chronic migraine.
Emgality is funded in many other OECD countries, including Australia, the United Kingdom, the United States and Canada. In New Zealand, people must pay around $325 per injection – 2 injections are needed at the beginning of treatment and then one injection every 4 weeks.
